Clinical importance of estrogen receptor-β evaluation in breast cancer patients treated with adjuvant tamoxifen therapy

Journal of Clinical Oncology

Volumn 26, Issue 22, 2008, Pages 3727-3734

  Honma, Naoko ^a   Horii, Rie ^a   Iwase, Takuji ^a   Saji, Shigehira ^a   Younes, Mamoun ^a   Takubo, Kaiyo ^a   Matsuura, Masaaki ^a   Ito, Yoshinori ^a   Akiyama, Futoshi ^a   Sakamoto, Goi ^a  

^a CANCER INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGEN RECEPTOR BETA ANTIBODY; ESTROGEN RECEPTOR BETA1; ESTROGEN RECEPTOR BETA2; ESTROGEN RECEPTOR BETA3; ESTROGEN RECEPTOR BETACX; ESTROGEN RECEPTOR BETAN; RECEPTOR ANTIBODY; TAMOXIFEN; UNCLASSIFIED DRUG; ERBB2 PROTEIN, HUMAN; ISOPROTEIN; PROGESTERONE RECEPTOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MONOTHERAPY; PRIORITY JOURNAL; PROGNOSIS; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; CANCER INVASION; CHEMISTRY; MENOPAUSE; MIDDLE AGED; MORTALITY; PATHOLOGY; SURVIVAL; TIME; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; ESTROGEN RECEPTOR BETA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MENOPAUSE; MIDDLE AGED; NEOPLASM INVASIVENESS; PROTEIN ISOFORMS; RECEPTOR, ERBB-2; RECEPTORS, PROGESTERONE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SURVIVAL ANALYSIS; TAMOXIFEN; TIME FACTORS; TREATMENT OUTCOME;

EID: 49249129393     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.14.2968     Document Type: Article

References (42)

1. Beatson GT: On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new method of treatment with illustrative cases. Lancet ii:104-107, 1896
2. Allred DC, Harvey JM, Berardo M, et al: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11:155-168, 1998
3. Savouret JF, Bailly A, Misrahi M, et al: Characterization of the hormone responsive element involved in the regulation of the progesterone receptor gene. Embo J 10:1875-1883, 1991
4. Kuiper GG, Enmark E, Pelto-Huikko M, et al: Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci U S A 93:5925-5930, 1996
5. Leygue E, Dotzlaw H, Watson PH, et al: Expression of estrogen receptor beta1, beta2, and beta5 messenger RNAs in human breast tissue. Cancer Res 59:1175-1179, 1999
6. Speirs V, Parkes AT, Kerin MJ, et al: Coexpression of estrogen receptor alpha and beta: Poor prognostic factors in human breast cancer? Cancer Res 59:525-528, 1999
7. Järvinen TAH, Pelto-Huikko M, Holli K, et al: Estrogen receptor beta is coexpressed with ERalpha and PR and associated with nodal status, grade, and proliferation rate in breast cancer. Am J Pathol 156:29-35, 2000
8. Mann S, Laucirica R, Carlson N, et al: Estrogen receptor beta expression in invasive breast cancer. Hum Pathol 32:113-118, 2001
9. Omoto Y, Inoue S, Ogawa S, et al: Clinical value of the wild-type estrogen receptor beta expression in breast cancer. Cancer Lett 163:207-212, 2001
10. Saji S, Omoto Y, Shimizu C, et al: Expression of estrogen receptor (ER) betacx protein in ERalpha-positive breast cancer: Specific correlation with progesterone receptor. Cancer Res 62:4849-4853, 2002
11. Skliris GP, Parkes AT, Limer JL, et al: Evaluation of seven oestrogen receptor beta antibodies for immunohistochemistry, Western blotting, and flow cytometry in human breast tissue. J Pathol 197:155-162, 2002
12. Speirs V: Oestrogen receptor beta in breast cancer: Good, bad or still too early to tell? J Pathol 197:143-147, 2002
13. Fuqua SAW, Schiff R, Parra I, et al: Estrogen receptor beta protein in human breast cancer: Correlation with clinical tumor parameters. Cancer Res 63:2434-2439, 2003
14. Balfe P, McCann A, McGoldrick A, et al: Estrogen receptor alpha and beta profiling in human breast cancer. Eur J Surg Oncol 30:469-474, 2004
15. Nakopoulou L, Lazaris AC, Panayotopoulou EG, et al: The favourable prognostic value of oestrogen receptor beta immunohistochemical expression in breast cancer. J Clin Pathol 57:523-528, 2004
16. O'Neill PA, Davies MPA, Shaaban AM, et al: Wild-type oestrogen receptor beta (ERbeta1) mRNA and protein expression in tamoxifen-treated postmenopausal breast cancers. Br J Cancer 91:1694-1702, 2004
17. Speirs V, Carder PJ, Lane S, et al: Oestrogen receptor beta: What it means for patients with breast cancer. Lancet Oncol 5:174-181, 2004
18. Saji S, Hirose M, Toi M: Clinical significance of estrogen receptor beta in breast cancer. Cancer Chemother Pharmacol 56:21-26, 2005 (suppl 1)
19. Miller WR, Anderson TJ, Dixon JM, et al: Oestrogen receptor beta and neoadjuvant therapy with tamoxifen: Prediction of response and effects of treatment. Br J Cancer 94:1333-1338, 2006
20. Murphy LC, Watson PH: Is oestrogen receptor-beta a predictor of endocrine therapy responsiveness in human breast cancer? Endocr Relat Cancer 13:327-334, 2006
21. Gruvberger-Saal SK, Bendahl PO, Saal LH, et al: Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma. Clin Cancer Res 13:1987-1994, 2007
22. Skliris GP, Carder PJ, Lansdown MRJ, et al: Immunohistochemical detection of ER-beta in breast cancer: Towards more detailed receptor profiling? Br J Cancer 84:1095-1098, 2001
23. Esslimani-Sahla M, Simony-Lafontaine J, Kramar A, et al: Estrogen receptor beta (ERbeta) level but not its ERbetacx variant helps to predict tamoxifen resistance in breast cancer. Clin Cancer Res 10:5769-5776, 2004
24. Moore JT, McKee DD, Slentz-Kesler K, et al: Cloning and characterization of human estrogen receptor beta isoforms. Biochem Biophys Res Commun 247:75-78, 1998
25. Ogawa S, Inoue S, Watanabe T, et al: Molecular cloning and characterization of human estrogen receptor betacx: A potential inhibitor of oestrogen action in human. Nucleic Acids Res 26:3505-3512, 1998
26. Weihua Z, Andersson S, Cheng G, et al: Update on estrogen signaling. FEBS Lett 546:17-24, 2003
27. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31000 recurrences and 24000 deaths among 75000 women. Lancet 339:1-15, 1992
28. Ellis IO, Schnitt SJ, Sastre-Garau X, et al: Invasive breast carcinoma, in Tavassoli FA, Devilee P (eds): World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon, France, International Agency for Research on Cancer Press, 2003, pp 13-48
29. Tsuda H, Akiyama F, Kurosumi M, et al: Establishment of histological criteria for high-risk node-negative breast carcinoma for a multiinstitutional randomized clinical trial of adjuvant therapy: Japan National Surgical Adjuvant Study of Breast Cancer (NSAS-BC) Pathology Section. Jpn J Clin Oncol 28:486-491, 1998
30. Tsuda H, Akiyama F, Kurosumi M, et al: Evaluation of the interobserver agreement in the number of mitotic figures of breast carcinoma as simulation of quality monitoring in the Japan National Surgical Adjuvant Study of Breast Cancer (NSAS-BC) protocol. Jpn J Cancer Res 91:451-457, 2000
31. Honma N, Takubo K, Akiyama F, et al: Expression of oestrogen receptor-beta in apocrine carcinomas of the breast. Histopathology 50:425-433, 2007
32. Cleator S, Heller W, Coombes RC: Triple-negative breast cancer: Therapeutic options. Lancet Oncol 8:235-244, 2007
33. Perou CM, Sørlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature 406:747-752, 2000
34. Roger P, Esslimani Sahla M, Mäkelä S, et al: Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res 61:2537-2541, 2001
35. Shaaban AM, O'Neill PA, Davies MPA, et al: Declining estrogen receptor-beta expression defines malignant progression of human breast neoplasia. Am J Surg Pathol 27:1502-1512, 2003
36. Shaaban AM, Jarvis C, Moore F, et al: Prognostic significance of estrogen receptor beta in epithelial hyperplasia of usual type with known outcome. Am J Surg Pathol 29:1593-1599, 2005
37. Hartman J, Lindberg K, Morani A, et al: Estrogen receptor-β inhibits angiogenesis and growth of T47D breast cancer xenografts. Cancer Res 66:11207-11213, 2006
38. Honma N, Takubo K, Sawabe M, et al: Estrogen-metabolizing enzymes in breast cancers from women over the age of 80 years. J Clin Endocrinol Metab 91:607-613, 2006
39. Vermeulen A, Deslypere JP, Paridaens R, et al: Aromatase, 17 beta-hydroxysteroid dehydrogenase and intratissular sex hormone concentrations in cancerous and normal glandular breast tissue in postmenopausal women. Eur J Cancer Clin Oncol 22:515-525, 1986
40. Szymczak J, Milewicz A, Thijssen JH, et al: Concentration of sex steroids in adipose tissue after menopause. Steroids 63:319-321, 1998
41. Kuiper G, Lemmen JG, Carlsson B, et al: Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β. Endocrinology 139:4252-4263, 1998
42. Sakamoto G, Sugano H: Pathology of breast cancer: Present and prospect in Japan. Breast Cancer Res Treat Suppl 18:S81-S83, 1991 (suppl 1)